Next Article in Journal
Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells
Next Article in Special Issue
Towards Targeting PI3K-Dependent Regulation of Gene Expression in Brain Cancer
Previous Article in Journal
Cancer Chemotherapy Specific to Acidic Nests
Previous Article in Special Issue
PI3K Signaling in Tissue Hyper-Proliferation: From Overgrowth Syndromes to Kidney Cysts
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessArticle
Cancers 2017, 9(4), 37; doi:10.3390/cancers9040037

Timp1 Promotes Cell Survival by Activating the PDK1 Signaling Pathway in Melanoma

1
Pharmacology Department, Universidade Federal de São Paulo, São Paulo 04039-032, Brazil
2
Center for Translational Investigation in Oncology/LIM 24, Cancer Institute of São Paulo, School of Medicine, University of São Paulo, São Paulo 01246-000, Brazil
Current address: Faculdade de Medicina da Santa Casa de São Paulo, São Paulo 01221-020, Brazil
*
Author to whom correspondence should be addressed.
Academic Editor: Marco Falasca
Received: 14 February 2017 / Revised: 12 April 2017 / Accepted: 14 April 2017 / Published: 21 April 2017
(This article belongs to the Special Issue PI3K/PDK1/Akt Pathways in Cancer)
View Full-Text   |   Download PDF [1836 KB, uploaded 21 April 2017]   |  

Abstract

High TIMP1 expression is associated with poor prognosis in melanoma, where it can bind to CD63 and β1 integrin, inducing PI3-kinase pathway and cell survival. Phosphatidylinositol (3,4,5)-trisphosphate (PIP3), generated under phosphatidylinositol-3-kinase (PI3K) activation, enables the recruitment and activation of protein kinase B (PKB/AKT) and phosphoinositide-dependent kinase 1 (PDK1) at the membrane, resulting in the phosphorylation of a host of other proteins. Using a melanoma progression model, we evaluated the impact of Timp1 and AKT silencing, as well as PI3K, PDK1, and protein kinase C (PKC) inhibitors on aggressiveness characteristics. Timp1 downregulation resulted in decreased anoikis resistance, clonogenicity, dacarbazine resistance, and in vivo tumor growth and lung colonization. In metastatic cells, pAKTThr308 is highly expressed, contributing to anoikis resistance. We showed that PDK1Ser241 and PKCβIISer660 are activated by Timp1 in different stages of melanoma progression, contributing to colony formation and anoikis resistance. Moreover, simultaneous inhibition of Timp1 and AKT in metastatic cells resulted in more effective anoikis inhibition. Our findings demonstrate that Timp1 promotes cell survival with the participation of PDK1 and PKC in melanoma. In addition, Timp1 and AKT act synergistically to confer anoikis resistance in advanced tumor stages. This study brings new insights about the mechanisms by which Timp1 promotes cell survival in melanoma, and points to novel perspectives for therapeutic approaches. View Full-Text
Keywords: Timp1; anoikis resistance; PI3K pathway; PDK1; PKC; melanoma Timp1; anoikis resistance; PI3K pathway; PDK1; PKC; melanoma
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Toricelli, M.; Melo, F.H.M.; Hunger, A.; Zanatta, D.; Strauss, B.E.; Jasiulionis, M.G. Timp1 Promotes Cell Survival by Activating the PDK1 Signaling Pathway in Melanoma. Cancers 2017, 9, 37.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top